[go: up one dir, main page]

HK1257298A1 - 硼的酯和酸化合物的合成 - Google Patents

硼的酯和酸化合物的合成

Info

Publication number
HK1257298A1
HK1257298A1 HK18116447.5A HK18116447A HK1257298A1 HK 1257298 A1 HK1257298 A1 HK 1257298A1 HK 18116447 A HK18116447 A HK 18116447A HK 1257298 A1 HK1257298 A1 HK 1257298A1
Authority
HK
Hong Kong
Prior art keywords
synthesis
acid compounds
boron ester
boron
ester
Prior art date
Application number
HK18116447.5A
Other languages
English (en)
Inventor
I．弗瑞瑟．皮克斯吉爾
約翰．比斯霍普
克里斯多夫．寇爾納
珍-馬克．高曼姿
艾奇.吉瑟
羅伯特‧賀特
文斯.艾默斯卡都
史蒂芬.蒙克
樓永
裘芬婷
維斯蘭納．R．庫爾卡尼
Original Assignee
千禧藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1257298(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 千禧藥品公司 filed Critical 千禧藥品公司
Publication of HK1257298A1 publication Critical patent/HK1257298A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
HK18116447.5A 2004-03-30 2018-12-21 硼的酯和酸化合物的合成 HK1257298A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30

Publications (1)

Publication Number Publication Date
HK1257298A1 true HK1257298A1 (zh) 2019-10-18

Family

ID=34968044

Family Applications (4)

Application Number Title Priority Date Filing Date
HK07107789.3A HK1100004A1 (en) 2004-03-30 2007-07-19 Synthesis of boronic ester and acid compounds
HK12103590.4A HK1164320A1 (en) 2004-03-30 2012-04-12 Synthesis of bortezomib
HK18105728.8A HK1246300A1 (zh) 2004-03-30 2018-05-03 硼的酯和酸化合物的合成
HK18116447.5A HK1257298A1 (zh) 2004-03-30 2018-12-21 硼的酯和酸化合物的合成

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK07107789.3A HK1100004A1 (en) 2004-03-30 2007-07-19 Synthesis of boronic ester and acid compounds
HK12103590.4A HK1164320A1 (en) 2004-03-30 2012-04-12 Synthesis of bortezomib
HK18105728.8A HK1246300A1 (zh) 2004-03-30 2018-05-03 硼的酯和酸化合物的合成

Country Status (41)

Country Link
US (14) US7714159B2 (zh)
EP (5) EP2377868A1 (zh)
JP (4) JP4558039B2 (zh)
KR (1) KR100939598B1 (zh)
CN (5) CN107474062A (zh)
AR (3) AR049374A1 (zh)
AT (1) ATE521612T1 (zh)
AU (1) AU2005230930B2 (zh)
BR (1) BRPI0509587A (zh)
CA (4) CA2859119A1 (zh)
CL (2) CL2010000350A1 (zh)
CR (1) CR8653A (zh)
CY (3) CY1112053T1 (zh)
DK (4) DK3385267T3 (zh)
DO (1) DOP2011000293A (zh)
EA (1) EA012927B1 (zh)
EC (1) ECSP066960A (zh)
ES (4) ES2974758T3 (zh)
FI (1) FI4008721T3 (zh)
HK (4) HK1100004A1 (zh)
HR (4) HRP20240307T3 (zh)
HU (2) HUE065769T2 (zh)
IL (3) IL178250A (zh)
LT (2) LT3385267T (zh)
ME (1) ME01975B (zh)
MX (1) MX367324B (zh)
MY (1) MY145427A (zh)
NL (3) NL1028639C2 (zh)
NO (4) NO338905B1 (zh)
NZ (3) NZ586824A (zh)
PE (3) PE20060162A1 (zh)
PL (4) PL3385267T3 (zh)
PT (4) PT2377869E (zh)
RS (4) RS53259B (zh)
SG (5) SG151322A1 (zh)
SI (4) SI3385267T1 (zh)
TW (1) TWI386212B (zh)
UA (1) UA90108C2 (zh)
UY (3) UY28830A1 (zh)
WO (1) WO2005097809A2 (zh)
ZA (1) ZA200608689B (zh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
PL3385267T3 (pl) * 2004-03-30 2022-02-14 Millennium Pharmaceuticals, Inc. Synteza związków estrów i kwasów boronowych
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
NZ582693A (en) 2007-08-06 2012-01-12 Millennium Pharm Inc Boron-containing proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
MX2010002836A (es) * 2007-09-12 2010-03-31 Reddys Lab Ltd Dr Bortezomib y proceso para la produccion del mismo.
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
SG10201701524XA (en) 2008-06-17 2017-04-27 Millennium Pharm Inc Boronate ester compounds and pharmaceutical compositions thereof
AU2013204874B2 (en) * 2008-09-29 2016-11-10 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
CA2765811C (en) * 2009-06-19 2018-06-05 Lek Pharmaceuticals D.D. Process for hydrogenation of halogenoalkenes without dehalogenation
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
CA2785300A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2534159A1 (en) 2010-02-09 2012-12-19 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
AU2011227083B2 (en) * 2010-03-18 2013-07-18 Innopharma, Inc. Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
JP5881254B2 (ja) 2010-05-18 2016-03-09 セルリアン・ファーマ・インコーポレイテッド 自己免疫疾患およびその他の疾患の治療のための組成物および方法
ES2548256T3 (es) 2010-10-14 2015-10-15 Synthon Bv Proceso para la preparación de bortezomib y los intermedios para el proceso
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
JP5944986B2 (ja) 2011-06-22 2016-07-05 セファロン、インク． プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
MX352652B (es) 2011-12-22 2017-12-04 Ares Trading Sa Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico.
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
BR112015005343A2 (pt) * 2012-09-11 2017-07-04 Cipla Ltd processo para a preparação de bortezomib, composto, bortezomib ou seu anidrido, e, processo para a preparação de um composto
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
US9217001B2 (en) 2012-11-16 2015-12-22 Shilpa Medicare Limited Crystalline bortezomib process
CA2893943C (en) 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014170628A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
TN2016000492A1 (en) 2014-05-20 2018-04-04 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy.
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151A1 (de) * 2015-03-09 2016-09-15 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
CN110312727A (zh) * 2017-02-17 2019-10-08 费森尤斯卡比肿瘤学有限公司 一种改进的制备硼酸酯的方法
CN117398398A (zh) 2017-03-06 2024-01-16 云顶新耀新加坡有限公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
CN109305980B (zh) 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
US10927133B2 (en) 2017-09-02 2021-02-23 Sun Pharmaceutical Industries Limited Process for the preparation of ixazomib citrate
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
US20250059215A1 (en) 2023-08-07 2025-02-20 Tae Life Sciences Llc Trifluoroborate (BF3) Compositions For Use In Boron Neutron Capture Therapy and Methods Thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31992A (en) * 1968-05-08 1973-07-30 American Cyanamid Co Synthetic thyrocalcitonins and method of making them
ZA794723B (en) * 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
US4525309A (en) 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
ES8603405A1 (es) * 1985-04-22 1985-12-16 Inke Sa "procedimiento para la obtencion del ester benzilico de 1-(n-(1--etoxicarbonil-3-oxo-fenilpropil)-l-alanil)-l-prolina".
SE8506094D0 (sv) * 1985-12-20 1985-12-20 Astra Laekemedel Ab New antibacterial agents and intermediates therefor
US4701545A (en) 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JP2004517932A (ja) * 2001-01-25 2004-06-17 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ボロン酸化合物製剤
JPWO2003033507A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003033506A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
PL3385267T3 (pl) 2004-03-30 2022-02-14 Millennium Pharmaceuticals, Inc. Synteza związków estrów i kwasów boronowych
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
CA2765811C (en) * 2009-06-19 2018-06-05 Lek Pharmaceuticals D.D. Process for hydrogenation of halogenoalkenes without dehalogenation

Also Published As

Publication number Publication date
HRP20140339T1 (hr) 2014-05-09
UY34969A (es) 2015-02-27
ECSP066960A (es) 2006-12-20
JP5414625B2 (ja) 2014-02-12
NO338905B1 (no) 2016-10-31
UA90108C2 (uk) 2010-04-12
JP2013100378A (ja) 2013-05-23
HK1164320A1 (en) 2012-10-19
NL1028639C2 (nl) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
CY1115336T1 (el) 2017-01-04
US20150038706A1 (en) 2015-02-05
DK1756121T3 (da) 2012-01-09
EP2377869B1 (en) 2014-01-29
AR097309A2 (es) 2016-03-02
IL219856A (en) 2015-05-31
UY35578A (es) 2016-01-08
JP2016056180A (ja) 2016-04-21
CY1124753T1 (el) 2022-07-22
EP2377869A1 (en) 2011-10-19
NO20064893L (no) 2006-12-22
LT4008721T (lt) 2024-03-25
EP3385267A1 (en) 2018-10-10
AR097310A2 (es) 2016-03-02
SG10201600029PA (en) 2016-02-26
RS65253B1 (sr) 2024-03-29
SI3385267T1 (sl) 2022-04-29
US9862745B2 (en) 2018-01-09
AU2005230930A1 (en) 2005-10-20
CR8653A (es) 2007-10-23
SG182999A1 (en) 2012-08-30
JP5894952B2 (ja) 2016-03-30
DK4008721T3 (da) 2024-03-25
CN111925385A (zh) 2020-11-13
PL3385267T3 (pl) 2022-02-14
US20200157143A1 (en) 2020-05-21
ES2371652T3 (es) 2012-01-05
PE20060162A1 (es) 2006-04-07
SI4008721T1 (sl) 2024-05-31
NZ598172A (en) 2013-08-30
MY145427A (en) 2012-02-15
JP4558039B2 (ja) 2010-10-06
CA2738706C (en) 2014-10-14
CN1960996B (zh) 2016-04-20
WO2005097809A3 (en) 2006-02-16
SG182998A1 (en) 2012-08-30
NO343966B1 (no) 2019-07-29
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
CN107474062A (zh) 2017-12-15
NL1033190C2 (nl) 2007-11-27
EA200601795A1 (ru) 2007-04-27
HRP20212002T1 (hr) 2022-04-01
KR20070007873A (ko) 2007-01-16
WO2005097809A2 (en) 2005-10-20
JP2010241816A (ja) 2010-10-28
CL2010000350A1 (es) 2011-01-28
SI2377869T1 (sl) 2014-05-30
JP2007530687A (ja) 2007-11-01
BRPI0509587A (pt) 2007-09-25
DK3385267T3 (da) 2021-11-01
EP1756121A2 (en) 2007-02-28
US20190112334A1 (en) 2019-04-18
US20180044377A1 (en) 2018-02-15
TW200616646A (en) 2006-06-01
US20220204558A1 (en) 2022-06-30
HUE056859T2 (hu) 2022-03-28
CN111925385B (zh) 2023-11-21
LT3385267T (lt) 2021-11-10
NO344610B1 (no) 2020-02-10
NO20171939A1 (no) 2006-12-22
NL1028639A1 (nl) 2005-10-20
AR049374A1 (es) 2006-07-26
HUE065769T2 (hu) 2024-06-28
EA012927B1 (ru) 2010-02-26
DOP2011000293A (es) 2011-12-15
FI4008721T3 (fi) 2024-03-19
CL2014002252A1 (es) 2014-12-05
NL1033189C2 (nl) 2008-08-14
PT2377869E (pt) 2014-04-15
US20190330270A1 (en) 2019-10-31
HK1246300A1 (zh) 2018-09-07
US7714159B2 (en) 2010-05-11
IL219856A0 (en) 2012-06-28
US8283467B2 (en) 2012-10-09
RS62738B1 (sr) 2022-01-31
US20100174072A1 (en) 2010-07-08
CN103396427B (zh) 2018-04-13
US10000529B2 (en) 2018-06-19
HRP20110846T1 (hr) 2011-12-31
IL219853A0 (en) 2012-06-28
ME01975B (me) 2015-05-20
NO20191065A1 (no) 2006-12-22
PL4008721T3 (pl) 2024-05-13
CN108329337A (zh) 2018-07-27
US20160362449A1 (en) 2016-12-15
ES2974758T3 (es) 2024-07-01
JP6193960B2 (ja) 2017-09-06
PT4008721T (pt) 2024-03-21
EP3385267B1 (en) 2021-09-29
ZA200608689B (en) 2007-09-26
SG10201800972PA (en) 2018-03-28
ES2457593T3 (es) 2014-04-28
CA2560886C (en) 2014-08-12
DK2377869T3 (da) 2014-04-14
EP1756121B1 (en) 2011-08-24
HK1100004A1 (en) 2007-08-31
CN108329337B (zh) 2021-06-25
NO20161350A1 (no) 2006-12-22
PT1756121E (pt) 2011-11-30
IL219853A (en) 2015-05-31
PL1756121T3 (pl) 2012-02-29
NL1033189A1 (nl) 2007-10-22
CY1112053T1 (el) 2015-11-04
NL1033190A1 (nl) 2007-04-23
US20210395301A1 (en) 2021-12-23
RS53259B (en) 2014-08-29
KR100939598B1 (ko) 2010-02-01
US20210171574A1 (en) 2021-06-10
PT3385267T (pt) 2021-11-23
IL178250A0 (en) 2006-12-31
US20200369722A1 (en) 2020-11-26
CN1960996A (zh) 2007-05-09
PE20110075A1 (es) 2011-02-17
EP4008721B1 (en) 2024-01-03
CA2738706A1 (en) 2005-10-20
MX367324B (es) 2019-08-15
CA2560886A1 (en) 2005-10-20
US20050240047A1 (en) 2005-10-27
EP2377868A1 (en) 2011-10-19
PE20142402A1 (es) 2015-02-04
SI1756121T1 (sl) 2012-03-30
AU2005230930B2 (en) 2011-09-29
EP4008721A1 (en) 2022-06-08
TWI386212B (zh) 2013-02-21
CA2859119A1 (en) 2005-10-20
ATE521612T1 (de) 2011-09-15
UY28830A1 (es) 2005-09-30
NZ586824A (en) 2012-03-30
NZ550522A (en) 2010-08-27
HRP20240307T3 (hr) 2024-05-10
PL2377869T3 (pl) 2014-07-31
SG151322A1 (en) 2009-04-30
IL178250A (en) 2012-06-28
US20180265546A1 (en) 2018-09-20
ES2899606T3 (es) 2022-03-14

Similar Documents

Publication Publication Date Title
HK1257298A1 (zh) 硼的酯和酸化合物的合成
LTPA2017004I1 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1871738T3 (da) N-alkylcarbonylaminosyreester- og N-alkylcarbonylaminolactonforbindelser og deres anvendelse
EP1957474A4 (en) SYNTHESIS OF FTSZ HEMMERN
IL179538A0 (en) Synthesis of amino-alkoxy-heptanoic alkyl ester
DK1798234T3 (da) Farmaceutisk sammensætning omfattende temozolomidester
FR2905057B1 (fr) Plaque de presentation support d'outils
ZA200900278B (en) Synthesis of 3-(5-nitrocyclohex-1-enyl)acrylic acid and esters thereof
HK1087098A1 (en) Synthesis of 2-chloromethyl-6-methylbenzoic acid esters
DOP2005000058A (es) Sintesis de compuestos de ester y acido borico
ATE402145T1 (de) Synthese von pyrrol-2-carbonsäurenitrilen
ITMI20042415A1 (it) Sintesi di alfa-aril-alfa-piperid-2-il-acetammidi e loro idrolisi acida
ITVR20040028A1 (it) Struttura di longherone
SI1611083T1 (sl) Sinteza estrov 2-klorometil-6-metil-benzojske kisline
GB0428166D0 (en) Use of essentially fatty acid molecules
UA8735S (uk) Комплект етикеток
UA11250S (uk) Комплект етикеток
UA11076S (uk) Комплект етикеток
UA10481S (uk) Комплект етикеток
UA11062S (uk) Комплект етикеток
UA10527S (uk) Комплект етикеток
UA10641S (uk) Набір етикеток
UA10953S (uk) Комплект етикеток
UA9909S (uk) Комплект етикеток

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20250320